This study tests a new medicine, CLN-049, for people with two types of blood diseases called Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). AML and MDS are types of cancer where the bone marrow makes unhealthy blood cells. The study has three parts:
- Part A: Patients get one dose of CLN-049 through an IV (a tube in the vein) and are checked for a month.
- Part B & C: Patients get multiple doses either through IV or under the skin and are checked for a month, then followed for up to 2 years.
Key Points:
- The study involves regular visits for check-ups and monitoring, and it may last up to 2 years.
- Participants should be willing to follow study rules and have tried other treatments without success.
- There are specific health conditions and treatments that might prevent someone from joining the study.
If you have AML or MDS and are interested, discuss with your doctor to see if this study might be right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand